BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
07 mai 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
06 mai 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 16h35 HE
|
BioAtla, Inc.
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
26 mars 2024 16h01 HE
|
BioAtla, Inc.
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
19 mars 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
07 mars 2024 08h00 HE
|
BioAtla, Inc.
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug...
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
20 déc. 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
13 déc. 2023 08h00 HE
|
BioAtla, Inc.
Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and...
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
06 déc. 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
05 déc. 2023 08h00 HE
|
BioAtla, Inc.
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints ...